Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1854 Views
Dr KK Aggarwal 01 December 2020
With input from Dr Monica Vasudev
1177 COVID-19 vaccine tracker
| Candidate | Type of vaccine | Sponsor | Phase of trial | |
AZD1222 | Replication-deficient viral vector vaccine (chimpanzee adenovirus) | The University of Oxford; AstraZeneca; IQVIA; Serum Institute of India | Phase 3 | ||
BNT162 | mRNA-based vaccine | Pfizer, BioNTech | Phase 3 | ||
mRNA-1273 | mRNA-based vaccine | Phase 3 | |||
Ad5-nCoV | Recombinant vaccine (adenovirus type 5 vector) | Phase 3 | |||
CoronaVac | Inactivated vaccine (formalin with alum adjuvant) | Phase 3 | |||
Covaxin | Inactivated vaccine | Bharat Biotech; National Institute of Virology | Phase 3 | ||
JNJ-78436735 | Non-replicating viral vector | Phase 3 | |||
Name not announced | Inactivated vaccine | Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) | Phase 3 | ||
NVX-CoV2373 | Nanoparticle vaccine | Phase 3 | |||
Sputnik V | Non-replicating viral vector | Gamaleya Research Institute, Acellena Contract Drug Research and Development | Phase 3 | ||
BCG vaccine | Live-attenuated vaccine | University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital | Phase 2/3 | ||
INO-4800 | DNA vaccine (plasmid) | Phase 2/3 | Center for Pharmaceutical Research, Kansas City. Mo.; University of Pennsylvania, Philadelphia | ||
VIR-7831 | Plant-based adjuvant vaccine | Medicago; GSK; Dynavax | Phase 2/3 | ||
Name not announced | Recombinant vaccine | Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences | Phase 2 | Various | |
ZyCoV-D | DNA vaccine (plasmid) | Phase 2 | |||
No name announced | Adjuvanted protein subunit vaccine | Phase 1/2 | |||
AG0301-COVID19 | DNA vaccine | Phase 1/2 | AnGes, Inc.; Japan Agency for Medical Research and Development | ||
BBIBP-CorV | Inactivated vaccine | Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) | Phase 1/2 | Henan Provincial Center for Disease Control and Prevention | |
EpiVacCorona | Peptide vaccine | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology | Phase 1/2 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology | |
GX-19 | DNA vaccine | Phase 1/2 | |||
LNP-nCoVsaRNA | Self-amplifying RNA vaccine | Phase 1/2 | |||
ARCT-021 (LUNAR-COV19) | Self-replicating RNA vaccine | Arcturus Therapeutics and Duke-NUS Medical School | Phase 1/2 | ||
Name not announced | Protein subunit vaccine | Sanofi; GlaxoSmithKline | Phase 1/2 | ||
No name announced | Inactivated vaccine | Chinese Academy of Medical Sciences, Institute of Medical Biology | Phase 1/2 | ||
AdimrSC-2f | Protein subunit vaccine | Phase 1 | |||
bacTRL-Spike | Monovalent oral vaccine (bifidobacteria) | Phase 1 | |||
COVAX-19 | Monovalent recombinant protein vaccine | Phase 1 | |||
CVnCoV | mRNA-based vaccine | Phase 1 | |||
DelNS1-2019-nCoV-RBD-OPT1 | Replicating viral vector | Xiamen University, Beijing Wantai Biological Pharmacy | Phase 1 | ||
GRAd-COV2 | Adenovirus-based vaccine | ReiThera; Leukocare; Univercells | Phase 1 | ||
UQ-CSL V451 | Protein subunit vaccine | CSL; The University of Queensland | Phase 1 | ||
No name announced | Adenovirus-based vaccine | ImmunityBio; NantKwest | Phase 1 | Phase 1 | |
SCB-2019 | Protein subunit vaccine | GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax; CEPI | Phase 1 | ||
UB-612 | Multitope peptide-based vaccine | Phase 1 | |||
V590 | Recombinant vaccine (vesicular stomatitis virus) | Merck; IAVI | Phase 1 | ||
V591 | Measles vector vaccine | Phase 1 | University of Pittsburgh; Themis Biosciences; Institut Pasteur | ||
VXA-CoV2-1 | Recombinant vaccine (adenovirus type 5 vector) | Phase 1 | |||
AAVCOVID | Gene-based vaccine | Massachusetts Eye and Ear; Massachusetts General Hospital; University of Pennsylvania | Pre-clinical | ||
AdCOVID | Intranasal vaccine | Pre-clinical | |||
ChAd-SARS-CoV-2-S | Adenovirus-based vaccine | Pre-clinical | |||
HaloVax | Self-assembling vaccine | Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc. | Pre-clinical | ||
HDT-301 | RNA vaccine | University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp | Pre-clinical | ||
LineaDNA | DNA vaccine | Pre-clinical | |||
MRT5500 | Recombinant vaccine | Sanofi, Translate Bio | Pre-clinical | ||
No name announced | Ii-Key peptide COVID-19 vaccine | Pre-clinical | |||
No name announced | Protein subunit vaccine | University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre | Pre-clinical | ||
No name announced | mRNA-based vaccine | Chulalongkorn University’s Center of Excellence in Vaccine Research and Development | Pre-clinical | ||
No name announced | gp96-based vaccine | Pre-clinical | |||
No name announced | Inactivated vaccine | Pre-clinical | |||
PittCoVacc | Recombinant protein subunit vaccine (delivered through microneedle array) | Pre-clinical | |||
T-COVIDTM | Intranasal vaccine | Pre-clinical |
[Source: raps.org]
Dr KK Aggarwal
President CMAAO, HCFI and Past National President IMA
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}